Skip Navigation
Home  Home | Contact us | How to find us | News | Accessibility
A member of Cambridge University Health Partners -

Dr Robert RintoulDr Robert Rintoul

Consultant Physician

Contact Details
Switchboard 01480 830541
Fax 01480 364331

Belinda Leadbetter
Tel 01480 364342

Respiratory Medicine.

Specialist Clinical Interests
Lung Cancer; Malignant Mesothelioma; Diagnostic bronchoscopy; Endobronchial and Endoscopic ultrasound.

Research Interests
Dr Rintoul’s research is focussed around clinical trials, translational research and tissue banking in malignant mesothelioma and the early detection of lung cancer.  He is Chief Investigator for multiple clinical studies including MesobanK, the national bioresource for malignant mesothelioma ( and holds grants from several major funding bodies.  Dr Rintoul is research lead for lung cancer for the Clinical Research Network Eastern and is a member of the British Thoracic Society Science and Research Committee.  Part funded by the Cambridge Biomedical Research Centre and the NCRI Clinical Research Network, he is co-lead for the Aerodigestive Programme of the Cambridge Cancer Centre.

Professional Profile
Dr Rintoul qualified in medicine from the University of Edinburgh and trained in respiratory medicine in London and Edinburgh.  He undertook his doctorate in the University of Edinburgh investigating mechanisms underlying resistance to chemotherapy in small cell lung cancer.  Dr Rintoul was appointed as a consultant in respiratory medicine specialising in thoracic oncology in 2005.  Currently he is lead clinician for cancer at Papworth Hospital NHS Foundation Trust and Director of the Papworth Hospital Clinical Trials Unit Collaboration and leads thoracic oncology research in Cambridge.

Education and Training
FRCP          Royal College of Physicians                       2008
PhD             University of Edinburgh                              2001
MRCP         Royal College of Physicians of Edinburgh    1995
MB ChB      University of Edinburgh                               1992
BSc (Hons) University of St Andrews                             1989

Current membership(s) of professional, national and regional bodies and university posts
Fellow of Royal College of Physicians 2008
General Medical Council Reg No. 3658334
Member of NHS England Lung Cancer Clinical Reference Group
Member of the British Thoracic Society Science and Research Committee
Member of British Thoracic Oncology Group
Member of the International Association for the Study of Lung Cancer

Selected Recent Publications

Kuijvenhoven JC, Korevaar DA, Tournoy KG, Malfait TL, Dooms C, Rintoul RC, Annema JT. Five-Year Survival After Endosonography vs Mediastinoscopy for Mediastinal Nodal Staging of Lung Cancer. JAMA. 2016 Sep 13;316(10):1110-2. doi: 10.1001 /jama.2016.10349.

Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, Eisen T, Gosney J, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rassl DM, Rintoul RC, Screaton NJ, Wald NJ, Weller D, Williamson PR, Yadegarfar G, Hansell DM. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016 Feb;71(2):161-70. doi: 10.1136/thoraxjnl-2015-207140. Epub 2015 Dec 8

Rintoul RC, Treasure T, Macbeth F. Multimodal treatment for malignant pleural mesothelioma. Lancet Oncol. 2015 Dec;16(16):1576-7. doi: 10.1016/S1470-2045(15)00253-3. Epub 2015 Nov 2. No abstract available

Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C. Key contribution of eIF4H-mediated translational control in tumor promotion. Oncotarget. 2015 Nov 24;6(37):39924-40. doi: 10.18632/oncotarget.5442.

Rintoul RC, Rassl DM, Gittins J, Marciniak SJ; MesobanK collaborators. MesobanK UK: an international mesothelioma bioresource. Thorax. 2016 Apr;71(4):380-2. doi: 10.1136/thoraxjnl-2015-207496. Epub 2015 Oct 14.

Treasure T, Rintoul RC, Macbeth F. SABR in early operable lung cancer: time for evidence. Lancet Oncol. 2015 Jun;16(6):597-8. doi: 10.1016/S1470-2045(15)70225-1. Epub 2015 May 13

Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, Dobson C, Rintoul RC, Hamilton W, Emery J. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study.  Br J Cancer. 2015 Mar 31;112 Suppl 1:S6-13. doi: 10.1038/bjc.2015.30

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Grönroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462.

Rintoul RC, Ahmed R, Dougherty B, Carroll NR Linear Endobronchial Ultrasonography: a novelty turned necessity for mediastinal nodal assessment. Thorax. 2015 Feb;70(2):175-80. doi: 10.1136/thoraxjnl-2014-205635. Epub 2014 Sep 21.

Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD; MesoVATS collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised controlled trial. Lancet. 2014 Jun 14. pii: S0140-6736(14)60418-9. doi: 10.1016/S0140-6736(14)60418-9. [Epub ahead of print]

McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, Holemans JA, Ledson M, Screaton N, Rintoul RC, Hands CJ, Lifford K, Whynes D, Kerr KM, Page R, Parmar M, Wald N, Weller D, Williamson PR, Myles J, Hansell DM, Duffy SW, Field JK. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014 Mar;7(3):362-71. doi: 10.1158/1940-6207.CAPR-13-0206. Epub 2014 Jan 17

Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, Rassl DM, Wang W, Forbes SJ, Gregory CD, Sethi T. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014 Mar 1;74(5):1554-65. doi: 10.1158/0008-5472.CAN-13-1541. Epub 2014 Jan 16.

Rintoul RC, Glover MJ, Jackson C, Hughes V, Tournoy KG, Dooms C, Annema JT, Sharples LD.Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective. Thorax. 2013 Sep 24. doi: 10.1136/thoraxjnl-2013-204374. [Epub ahead of print]

Dalton LE, Clarke HJ, Knight J, Lawson MH, Wason J, Lomas DA, Howat WJ, Rintoul RC, Rassl DM, Marciniak SJ. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer. 2013 Feb 14. doi: 10.1038/bjc.2013.66. [Epub ahead of print]

Sharples LD, Jackson C, Wheaton E, Griffith G, Annema JT, Dooms C, Tournoy KG, Deschepper E, Hughes V, Magee L, Buxton M, Rintoul RC. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial. Health Technol Assess. 2012;16(18):1-75, iii-iv.


How helpful did you find this page?

Not helpful Not helpful    12  3 4 5 67  8 9 10   Very helpful Very helpful

Latest News

Social Media